Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231258 | PMC |
| http://dx.doi.org/10.4103/0974-2700.142610 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?
Reprod Biol Endocrinol
January 2025
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Breast cancer (BrCa) is a complex and heterogeneous disease with diverse molecular subtypes, leading to varied clinical outcomes and posing significant treatment challenges. The increasing global burden of BrCa, particularly in low- and middle-income countries, underscores the urgent need for more effective therapeutic strategies. The androgen receptor (AR), expressed in a substantial proportion of breast cancer cases, has emerged as a potential biomarker and therapeutic target.
View Article and Find Full Text PDFTranscriptome analysis reveals the different toxic mechanism of three HBCD diastereoisomers to Brachionus plicatilis based on chemical defensome.
J Hazard Mater
January 2025
Department of Marine Ecology, College of Marine Life Sciences, Ocean University of China, No.5 Yushan Road, Qingdao, China; Laboratory for Marine Ecology and Environmental Science, Qingdao Marine Science and Technology Center, Qingdao, China. Electronic address:
The emerging contaminants hexabromocyclododecanes (HBCDs) are proved to exhibit highly reproductive toxicity to marine rotifer Brachionus plicatilis, but how about the toxic differentiation among three diastereoisomers of HBCD, and what's the possible hidden mechanism? B. plicatilis was exposed to different concentrations of HBCD diastereoisomers, and the results showed that α-, β- and γ-HBCD exhibited various toxicity on it, the adverse effects on individual life history traits included shortened lifespan, shortened body length and reduced offspring number. Population dynamics analysis showed that the maximum population density and time to reach it were also significantly influenced.
View Article and Find Full Text PDFPathological diagnosis of central nervous system tumours in adults: what's new?
Pathology
December 2024
Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
In the course of the last decade, the pathological diagnosis of many tumours of the central nervous system (CNS) has transitioned from a purely histological to a combined histological and molecular approach, resulting in a more precise 'histomolecular diagnosis'. Unfortunately, translation of this refinement in CNS tumour diagnostics into more effective treatment strategies is lagging behind. There is hope though that incorporating the assessment of predictive markers in the pathological evaluation of CNS tumours will help to improve this situation.
View Article and Find Full Text PDFImpulse control disorders in Parkinson's disease: What's new?
J Neurol
January 2025
Parkinson's Disease Research Clinic, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson's disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD.
View Article and Find Full Text PDF[Pneumology : what's new in 2024].
Rev Med Suisse
January 2025
Faculté de biologie et médecine, Université de Lausanne, 1005 Lausanne.
In 2024, several important innovations have enriched the management of respiratory diseases, including pulmonary hypertension, tuberculosis, COPD, and obstructive sleep apnea syndrome (OSAS). Notable advancements include the introduction of sotatercept in Switzerland for pulmonary arterial hypertension and mediastinal cryobiopsies, reflecting a shift toward more personalized medicine. Meanwhile, biologic therapies for COPD offer promising perspectives, and a potential path is emerging for shortening the treatment of certain forms of tuberculosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!